# Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis

Source: https://onco.cc/trials/nct04724980/  
OnCo record `nct04724980` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of PRGN-2012 - Phase I; Dose Level 1 in rare cancers of childhood, run by Precigen, Inc, active and no longer recruiting.

## Summary

Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis is a phase 1/2 interventional study registered as NCT04724980 by Precigen, Inc, with 38 participants enrolled, started 2021-03-16 and due to reach its primary completion in 2024-06-05. Interventions recorded: PRGN-2012 - Phase I; Dose Level 1, PRGN-2012 - Phase I; Dose Level 2 and PRGN-2012 - Phase II; Dose Level 2.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04724980
- Phase: 1/2
- Setting: A Phase 1/2 Study of Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
- Sponsor: Precigen, Inc
- Enrolled: 38

## Sources

- ClinicalTrials.gov NCT04724980: https://clinicaltrials.gov/study/NCT04724980

## Connected records

- cancers: [Rare cancers of childhood (NCI PDQ umbrella)](https://onco.cc/cancers/rare-childhood-cancers/)

---
JSON: https://onco.cc/api/v1/entities/nct04724980.json